Další formáty:
BibTeX
LaTeX
RIS
@proceedings{2247562, author = {Behrens, F. and Taylor, P. C. and Wetzel, D. and Brun, N. C. and BrandtandJuergens, J. and Drescher, E. and Dokoupilová, Eva and RowinskaandOsuch, A. and Martin, N. AbdelandKader and de Vlam, K.}, doi = {http://dx.doi.org/10.1136/annrheumdis-2022-eular.536}, keywords = {Izokibep; ABY-035; psoriatic arthriris; clinical trial}, language = {eng}, title = {IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY}, url = {https://ard.bmj.com/content/81/Suppl_1/170}, year = {2022} }
TY - CONF ID - 2247562 AU - Behrens, F. - Taylor, P. C. - Wetzel, D. - Brun, N. C. - Brandt-Juergens, J. - Drescher, E. - Dokoupilová, Eva - Rowinska-Osuch, A. - Martin, N. Abdel-Kader - de Vlam, K. PY - 2022 TI - IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY KW - Izokibep KW - ABY-035 KW - psoriatic arthriris KW - clinical trial UR - https://ard.bmj.com/content/81/Suppl_1/170 N2 - Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease with heterogenous musculoskeletal manifestation (arthritis, spondylitis, enthesitis, dactylitis) and extra-musculoskeletal manifestation (skin and nail psoriasis). In addition, PsA is commonly associated with comorbidities such as metabolic syndrome and cardiovascular diseases where IL-17 is a key driver of this disease. Izokibep is a unique IL-17A inhibitor with extraordinary potency and small molecular size designed to overcome the limitations of monoclonal antibodies such as poor tissue distribution. Here, we report 16-week phase 2 results in patients with active PsA. ER -
BEHRENS, F., P. C. TAYLOR, D. WETZEL, N. C. BRUN, J. BRANDT-JUERGENS, E. DRESCHER, Eva DOKOUPILOVÁ, A. ROWINSKA-OSUCH, N. Abdel-Kader MARTIN a K. DE VLAM. \textit{IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY}. 2022. ISSN~0003-4967. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2022-eular.536.
|